December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Biomind Labs Inc.

News headline image
Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada
From Biomind Labs Inc.
Via ACCESS Newswire
Tickers BMNDF
News headline image
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
From Biomind Labs Inc.
Via Business Wire
Tickers BMNDF
News headline image
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression
From Biomind Labs Inc.
Via Business Wire
News headline image
Biomind Labs Completes Development of a Thermosensitive Nasal Gel Pharmaceutical Dosage Form
From Biomind Labs Inc.
Via Business Wire
News headline image
Biomind Labs to Advance a Phase II Clinical Trial on DMT for Treatment-Resistant Depression
From Biomind Labs Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.